Global Myxoma Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Myxoma Market Overview

The global Myxoma market was valued at USD 20.50 billion in 2025 and is projected to reach USD 33.92 billion by 2033, growing at a CAGR of 6.50% from 2026 to 2033. The market is experiencing consistent growth driven by rising demand for safe and realistic driver training solutions, rapid advancements in simulation hardware and software, and expanding applications across automotive R&D, defense, and professional motorsport.

The increasing incidence of road accidents globally, combined with stricter government regulations on driver training and road safety, is compelling transportation authorities, driving schools, and military organizations to adopt advanced simulation technologies. Fixed-base and VR/AR-enabled simulators are replacing traditional on-road training in many markets, offering cost-effective, repeatable, and risk-free environments for skill development and autonomous vehicle validation.

Key Market Trends & Insights

• North America dominated the global Myxoma market with the largest revenue share of 36.42% in 2025, supported by advanced cardiovascular healthcare infrastructure, increasing adoption of minimally invasive cardiac surgeries, and growing availability of advanced imaging technologies for early tumor diagnosis.
• The Cardiac Myxoma segment led the market with a 44.18% share in 2025, driven by the higher clinical prevalence of primary cardiac tumors, rising awareness regarding early diagnosis, and increasing demand for surgical intervention and advanced cardiac monitoring solutions.
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 7.3% from 2026 to 2033, fueled by improving healthcare infrastructure, rising awareness regarding rare cardiovascular disorders, and expanding diagnostic capabilities across China, India, and Japan.
• The Imaging Tests segment is the fastest-growing diagnosis category, projected to register a CAGR of 7.1%, reflecting the growing adoption of echocardiography, MRI, CT scans, and advanced cardiac imaging technologies for accurate tumor detection and treatment planning.
• The Surgery segment dominates the treatment category with a 58.64% revenue share in 2025, led by increasing preference for surgical tumor excision as the primary treatment approach for cardiac and intramuscular myxomas.
• Hospital end-users account for 61.28% of the market, preferred for their advanced cardiac care infrastructure, multidisciplinary surgical teams, and availability of specialized diagnostic and post-operative care services.
• The surgery segment dominated the market with a share of 71.36% in 2025 due to its status as the primary and most effective treatment approach for cardiac and soft tissue myxomas.

Market Size & Forecast

• Global Market Value (2025): USD 20.50 Billion
• Expected Market Value (2033): USD 33.92 Billion
• Forecast CAGR (2026–2033): 6.50%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia-Pacific

Report Scope and Global Myxoma Market Segmentation

Global Myxoma Market Trends

Trend: Increasing Adoption of Advanced Cardiac Imaging and Minimally Invasive Surgical Approaches

Healthcare providers are increasingly adopting advanced cardiac imaging technologies and minimally invasive surgical techniques for the diagnosis and treatment of myxoma, particularly cardiac myxoma cases. Echocardiography, cardiac MRI, and CT imaging are playing a critical role in improving early tumor detection, accurate localization, and pre-surgical planning, enabling faster clinical intervention and reducing complication risks. Hospitals and specialty cardiac centers are also leveraging minimally invasive cardiac surgeries and robotic-assisted procedures to improve patient recovery time, reduce surgical trauma, and enhance long-term outcomes. In addition, growing awareness regarding rare cardiac tumors and increasing utilization of precision diagnostic tools are accelerating adoption of advanced treatment approaches across developed healthcare markets. According to clinical research studies, cardiac myxoma accounts for nearly 50% of all primary benign cardiac tumors globally, highlighting the growing importance of early diagnosis and timely surgical management.

Global Myxoma Market Dynamics

Key Market Driver: Rising Prevalence of Cardiac Tumors and Increasing Adoption of Advanced Diagnostic Imaging

The increasing prevalence of rare cardiac tumors and growing awareness regarding early tumor diagnosis are creating substantial demand for advanced myxoma treatment solutions globally. According to data published by the National Center for Biotechnology Information (NCBI), cardiac myxoma represents the most common type of primary cardiac tumor in adults, with women accounting for a significant proportion of diagnosed cases. Healthcare providers and specialty cardiac centers are increasingly investing in advanced imaging technologies including transesophageal echocardiography, MRI, and CT scanning to improve diagnostic accuracy and reduce treatment delays. In addition, growing adoption of minimally invasive cardiac surgery and improved post-operative monitoring systems are enhancing patient outcomes and reducing recurrence risks. Rising healthcare expenditure, expanding access to specialty cardiology services, and increasing awareness regarding symptoms such as shortness of breath, dizziness, chest pain, and stroke-like complications are further accelerating market growth globally.

Key Restraint/Challenge: High Surgical Costs and Limited Availability of Specialized Cardiac Care

A significant restraint in the global Myxoma market is the high treatment cost associated with advanced cardiac imaging, open-heart surgery procedures, and long-term post-operative monitoring. Surgical removal remains the primary treatment option for cardiac myxoma, often requiring highly specialized cardiothoracic surgical expertise, intensive care support, and advanced hospital infrastructure, significantly increasing overall healthcare expenditure. For instance, cardiac tumor surgeries in developed healthcare markets can cost tens of thousands of dollars depending on surgical complexity, hospitalization duration, and imaging requirements. In many low- and middle-income countries, limited access to specialized cardiac surgeons, delayed diagnosis, and inadequate healthcare infrastructure continue to restrict timely treatment adoption. The rarity of the disease and lack of awareness among patients and primary healthcare providers further contribute to delayed clinical intervention and limited market penetration across emerging healthcare systems.

Key Market Opportunity: Expansion of AI-Assisted Cardiac Imaging and Precision Surgical Technologies

The growing focus on AI-assisted diagnostic imaging and precision cardiac surgery presents a significant market opportunity for the Myxoma market. Advances in artificial intelligence, real-time cardiac imaging analytics, and robotic-assisted surgical systems are supporting the development of more accurate and efficient diagnosis and treatment strategies for cardiac and soft tissue myxomas. For instance, increasing adoption of AI-powered echocardiography and MRI analysis systems across the U.S., Germany, and Japan is improving early detection rates and enhancing surgical planning efficiency for complex cardiac tumors. In addition, collaborations between medical device companies, cardiac research institutes, and specialty hospitals are accelerating innovation in minimally invasive tumor management technologies. Expanding healthcare infrastructure, rising investments in advanced cardiology care, and improving access to imaging technologies across Asia-Pacific and Latin America are also creating substantial growth opportunities for healthcare providers and medical technology manufacturers globally.

Global Myxoma Market Scope

The Myxoma market is segmented on the basis of disease type, treatment, diagnosis, symptoms, dosage, route of administration, end-users, and distribution channel.

By Disease Type

On the basis of disease type, the global Myxoma market is segmented into conjunctival myxoma, intramuscular myxomas, cardiac myxoma, and cutaneous myxoma. The cardiac myxoma segment dominated the market with a share of 44.82% in 2025 due to its high clinical prevalence among primary cardiac tumors and increasing diagnosis through advanced echocardiography and cardiac imaging technologies. Rising awareness regarding early detection of cardiac abnormalities, growing adoption of minimally invasive cardiac surgeries, and increasing healthcare expenditure across developed economies are further supporting the strong dominance of this segment. In addition, hospitals and specialty cardiac centers are increasingly utilizing MRI and CT imaging for accurate tumor localization and surgical planning, improving treatment outcomes and reducing complication risks. The growing burden of cardiovascular disorders and rising incidence of symptoms such as shortness of breath, dizziness, palpitations, and stroke-like complications are also contributing to higher diagnosis rates globally. Favorable reimbursement policies for cardiac surgeries and increasing availability of specialty cardiology services further reinforce segment growth. Continuous advancements in robotic-assisted surgeries and post-operative monitoring technologies are In addition supporting the leading position of the cardiac myxoma segment in the global market.

The intramuscular myxomas segment is expected to witness the fastest CAGR of 6.9% from 2026 to 2033, driven by increasing awareness regarding rare soft tissue tumors and rising adoption of advanced imaging technologies for early diagnosis. Growing investments in orthopedic oncology care, increasing availability of MRI-based tumor detection systems, and rising healthcare access across emerging economies are accelerating segment growth. In addition, increasing collaborations between research institutes and healthcare providers for rare tumor management are improving treatment accessibility and supporting clinical advancements. The rising prevalence of musculoskeletal abnormalities and growing demand for minimally invasive surgical procedures are further contributing to market expansion. Expanding healthcare infrastructure and growing focus on personalized treatment planning are also expected to support long-term segment development globally.

By Treatment

On the basis of treatment, the global Myxoma market is segmented into surgery and others. The surgery segment dominated the market with a share of 71.36% in 2025 due to its status as the primary and most effective treatment approach for cardiac and soft tissue myxomas. Surgical excision is widely adopted to prevent severe complications including embolism, stroke, heart failure, and obstruction of blood flow caused by tumor progression. Increasing adoption of minimally invasive cardiac surgery, robotic-assisted surgical systems, and advanced perioperative monitoring technologies are improving patient outcomes and reducing recovery time. In addition, rising investments in specialty cardiac hospitals, growing availability of experienced cardiothoracic surgeons, and increasing awareness regarding timely tumor removal are reinforcing the strong dominance of the surgery segment globally. Hospitals are also increasingly utilizing precision imaging technologies for pre-surgical planning and post-operative monitoring, enhancing procedural success rates. The growing burden of rare cardiac tumors and improved healthcare accessibility across developed economies continue to strengthen segment demand.

The others segment is expected to witness the fastest CAGR of 5.8% from 2026 to 2033, driven by growing research activities focused on supportive therapies, symptom management, and post-surgical rehabilitation approaches. Increasing utilization of anti-inflammatory medications, anticoagulants, and long-term cardiac monitoring solutions is supporting segment expansion. Rising clinical research on targeted therapies and improved supportive care for patients with recurrent or complex myxoma conditions are also contributing to future growth opportunities across specialty healthcare centers globally.

By Diagnosis

On the basis of diagnosis, the global Myxoma market is segmented into complete blood count, imaging tests, and others. The imaging tests segment dominated the market with a share of 57.42% in 2025 due to its critical role in accurate tumor detection, localization, and surgical planning. Echocardiography, MRI, CT scans, and ultrasound imaging are widely utilized for diagnosing cardiac and soft tissue myxomas owing to their high precision and non-invasive capabilities. Increasing adoption of AI-assisted imaging technologies, rising investments in diagnostic infrastructure, and growing awareness regarding early tumor diagnosis are accelerating segment growth globally. Hospitals and specialty diagnostic centers are increasingly integrating advanced imaging platforms with real-time analytics to improve clinical accuracy and reduce diagnostic delays. In addition, growing healthcare expenditure and expanding access to advanced radiology services are supporting broader utilization of imaging technologies across emerging healthcare markets. The increasing prevalence of cardiovascular complications associated with cardiac myxoma is further driving demand for advanced diagnostic solutions.

The complete blood count segment is expected to witness the fastest CAGR of 6.1% from 2026 to 2033, driven by increasing utilization of laboratory screening procedures during preliminary patient assessment and disease monitoring. Rising adoption of integrated diagnostic workflows and growing focus on comprehensive pre-surgical evaluation are supporting segment expansion. In addition, increasing healthcare awareness and improving laboratory infrastructure across developing economies are expected to contribute to steady segment growth globally.

By Symptoms

On the basis of symptoms, the global Myxoma market is segmented into difficulty breathing, tiredness, shortness of breath, fainting, coughing, palpitations, dizziness, fever, flu-like illness, chest pain, stroke, and others. The shortness of breath segment dominated the market with a share of 18.84% in 2025 due to its high prevalence among patients diagnosed with cardiac myxoma and related cardiovascular complications. Increasing awareness regarding cardiovascular symptoms and growing utilization of echocardiography for patients presenting with respiratory distress are contributing significantly to segment growth. Hospitals and specialty cardiac centers are increasingly focusing on early detection of myxoma-associated complications to reduce risks of embolism, heart obstruction, and stroke. In addition, rising healthcare expenditure, increasing prevalence of cardiovascular disorders, and growing access to specialty cardiology services are reinforcing the segment’s leading market position globally. The rising aging population and growing burden of chronic heart conditions are also contributing to increased diagnosis rates.

The stroke segment is expected to witness the fastest CAGR of 6.4% from 2026 to 2033, driven by increasing awareness regarding embolic complications associated with untreated cardiac myxoma. Growing adoption of advanced neuroimaging technologies and rising focus on emergency cardiovascular care are accelerating segment growth. In addition, increasing clinical research regarding the neurological impact of cardiac tumors and improved patient monitoring technologies are further supporting expansion of this segment globally.

By Dosage

On the basis of dosage, the global Myxoma market is segmented into injection, tablets, and others. The injection segment dominated the market with a share of 53.28% in 2025 due to the widespread clinical use of injectable medications for perioperative care, anticoagulation therapy, pain management, and post-surgical recovery support. Hospitals and specialty cardiac centers increasingly prefer injectable formulations for rapid therapeutic response and controlled administration during surgical procedures and intensive care management. In addition, increasing adoption of hospital-based treatment protocols and growing use of injectable supportive therapies are reinforcing segment dominance globally. Rising hospitalization rates for cardiac surgeries and improved availability of advanced injectable formulations are also contributing to higher segment demand.
The tablets segment is expected to witness the fastest CAGR of 6.3% from 2026 to 2033, driven by increasing use of oral supportive medications during long-term recovery and follow-up care. Growing patient preference for convenient dosage formats and expanding availability of prescription cardiovascular medications are supporting segment expansion. In addition, increasing outpatient treatment management and rising healthcare accessibility across emerging economies are expected to accelerate growth of the tablets segment globally.

By Route of Administration

On the basis of route of administration, the global Myxoma market is segmented into oral, intravenous, and others. The intravenous segment dominated the market with a share of 49.63% in 2025 due to its extensive use in surgical procedures, emergency cardiac care, and hospital-based supportive therapies. Intravenous administration provides rapid therapeutic action and precise dosage control, making it highly preferred across specialty cardiac hospitals and intensive care units. Increasing adoption of advanced infusion technologies and rising investments in hospital infrastructure are further supporting the strong dominance of this segment globally. In addition, growing demand for perioperative medications and post-surgical recovery support continues to reinforce segment growth.

The oral segment is expected to witness the fastest CAGR of 6.5% from 2026 to 2033, driven by increasing utilization of long-term supportive therapies and rising patient preference for convenient medication administration. Growing adoption of outpatient care models, expanding access to prescription medications, and improving healthcare accessibility across emerging regions are further contributing to segment expansion globally. In addition, the increasing availability of oral cardiovascular supportive drugs and pain management therapies is improving treatment adherence and patient convenience during post-surgical recovery. Rising investments in pharmaceutical distribution networks and expanding retail pharmacy penetration across developing economies are also supporting stronger access to oral medications. Furthermore, growing focus on reducing hospital stays and minimizing healthcare costs is encouraging healthcare providers to adopt oral therapeutic approaches for long-term disease management and follow-up care.

By End-Users

On the basis of end-users, the global Myxoma market is segmented into clinic, hospital, and others. The hospital segment dominated the market with a share of 64.42% in 2025 due to the high requirement for advanced diagnostic imaging, surgical intervention, and intensive cardiac monitoring associated with myxoma treatment. Hospitals remain the primary centers for cardiac surgeries, MRI diagnostics, echocardiography procedures, and post-operative patient management. Increasing investments in specialty cardiology departments, rising availability of advanced surgical technologies, and growing patient preference for multi-specialty healthcare facilities are further strengthening segment dominance globally. In addition, expanding healthcare infrastructure and rising hospitalization rates for cardiovascular disorders are contributing to strong segment growth.

The clinic segment is expected to witness the fastest CAGR of 6.0% from 2026 to 2033, driven by increasing adoption of outpatient diagnostic consultations and growing access to specialty cardiovascular care services. Rising awareness regarding early symptom evaluation and increasing availability of referral-based diagnostic services are supporting segment expansion. In addition, improving healthcare accessibility and expanding specialty clinic networks across emerging economies are expected to contribute to future market growth.

By Distribution Channel

On the basis of distribution channel, the global Myxoma market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market with a share of 52.18% in 2025 due to the high volume of hospital-administered medications, injectable therapies, and post-surgical supportive treatments required during myxoma management. Hospital pharmacies play a critical role in ensuring immediate access to specialized cardiovascular medications, perioperative drugs, and intensive care therapeutics. Increasing hospitalization rates, growing surgical procedure volumes, and rising investments in hospital infrastructure are reinforcing the segment’s leading position globally. In addition, expanding specialty cardiac care centers and improved healthcare reimbursement systems are supporting higher medication utilization through hospital pharmacies.

The online pharmacy segment is expected to witness the fastest CAGR of 6.7% from 2026 to 2033, driven by increasing digital healthcare adoption, rising e-pharmacy penetration, and growing patient preference for convenient medicine purchasing platforms. Expanding internet accessibility, improved prescription delivery systems, and increasing telehealth integration are accelerating segment growth globally. In addition, growing focus on remote patient management and expanding healthcare access across underserved regions are expected to create substantial opportunities for online pharmacy providers during the forecast period.

Global Myxoma Market Regional Analysis

North America dominated the Myxoma market and accounted for the largest revenue share of 36.42% in 2025, supported by advanced cardiovascular healthcare infrastructure, increasing adoption of minimally invasive cardiac surgeries, and growing availability of advanced imaging technologies for early tumor diagnosis. The region also benefits from strong presence of specialty cardiac hospitals, high healthcare expenditure, and rising adoption of MRI, CT, and echocardiography technologies for accurate detection of cardiac myxoma and related tumors. Increasing focus on precision cardiology, early diagnosis of rare cardiac disorders, and continuous advancements in robotic-assisted cardiac surgeries continue to strengthen North America’s leadership position in the global market.

U.S. Myxoma Market Insight

The U.S. Myxoma market is witnessing strong growth due to rising investments in advanced cardiovascular care, increasing awareness regarding rare cardiac tumors, and growing adoption of minimally invasive cardiac surgery technologies. The country’s highly developed healthcare ecosystem, along with increasing utilization of AI-assisted imaging systems, echocardiography, and MRI-based diagnostics, is driving demand across hospitals, specialty cardiac centers, and research institutions. In addition, growing focus on reducing cardiovascular complications and improving early tumor detection rates is accelerating adoption of advanced myxoma diagnosis and treatment solutions across the United States.

Europe Myxoma Market Insight

The Europe Myxoma market remains a major contributor to global revenue, driven by strong healthcare infrastructure, technological innovation, and high demand for advanced cardiovascular diagnostic solutions. The widespread adoption of minimally invasive cardiac surgeries, advanced cardiac imaging systems, and specialty cardiology services is supporting market expansion across the region. Increasing investments in precision medicine, coupled with strong government support for cardiovascular disease management and highly developed healthcare systems, continue to enhance the adoption of Myxoma treatment solutions throughout Europe.

U.K. Myxoma Market Insight

The U.K. Myxoma market is experiencing steady growth, supported by increasing awareness regarding cardiovascular tumor diagnosis and rising adoption of advanced cardiac imaging technologies. Growing investments in specialty cardiac care infrastructure and increasing demand for minimally invasive treatment approaches are contributing to market growth. Furthermore, integration of AI-assisted diagnostic imaging, robotic surgery technologies, and advanced post-operative monitoring systems is improving treatment efficiency and patient outcomes, positioning the U.K. as a key innovation hub in the Myxoma market.

Germany Myxoma Market Insight

The Germany Myxoma market is expanding steadily due to the country’s strong healthcare infrastructure, advanced research capabilities, and increasing adoption of next-generation cardiac imaging technologies. Hospitals, research institutions, and specialty cardiac centers are increasingly utilizing MRI, CT imaging, and minimally invasive surgical systems for accurate diagnosis and treatment planning. Continuous advancements in robotic-assisted cardiac surgeries, AI-integrated imaging platforms, and precision cardiology technologies, along with strong government focus on healthcare innovation, are further driving market growth in Germany.

Asia-Pacific Myxoma Market Insight

The Asia-Pacific Myxoma market is expected to witness rapid growth, driven by improving healthcare infrastructure, rising awareness regarding rare cardiovascular disorders, and expanding diagnostic capabilities across countries such as China, India, and Japan. Growing adoption of advanced imaging technologies, increasing healthcare expenditure, and rising demand for early diagnosis and minimally invasive cardiac treatments are supporting regional market expansion. In addition, increasing investments in specialty cardiology centers, expanding access to advanced healthcare services, and rising prevalence of cardiovascular complications are accelerating adoption of Myxoma treatment solutions across the region.

Japan Myxoma Market Insight

The Japan Myxoma market is witnessing consistent growth due to rising investments in advanced cardiovascular diagnostics, healthcare innovation, and early cardiac disease detection programs. Hospitals and specialty cardiac centers are increasingly adopting high-precision MRI, echocardiography, and robotic-assisted surgery technologies for improved tumor diagnosis and treatment outcomes. Moreover, increasing integration of AI-assisted diagnostic systems and the country’s focus on efficient and high-quality healthcare services are further contributing to market growth.

China Myxoma Market Insight

The China Myxoma market is growing rapidly, driven by expanding healthcare infrastructure, rising government focus on cardiovascular disease management, and increasing awareness regarding rare cardiac tumors. Growing adoption of advanced imaging systems and minimally invasive surgical technologies across hospitals and specialty cardiac centers is significantly boosting market demand. In addition, rising healthcare investments, increasing access to specialty cardiology services, and rapid technological advancements in diagnostic imaging are positioning China as one of the fastest-growing markets for Myxoma globally.

Global Myxoma Market Share

The Myxoma industry is primarily led by well-established companies, including:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Pfizer Inc. (U.S.)
• Novartis AG (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• AbbVie Inc. (U.S.)
• Sanofi S.A. (France)
• AstraZeneca PLC (U.K.)
• GlaxoSmithKline plc (U.K.)
• Merck & Co., Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• Bayer AG (Germany)
• Amgen Inc. (U.S.)
• Takeda Pharmaceutical Company Limited (Japan)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Boehringer Ingelheim International GmbH (Germany)
• Abbott Laboratories (U.S.)
• Siemens Healthineers AG (Germany)
• GE HealthCare Technologies Inc. (U.S.)
• Koninklijke Philips N.V. (Netherlands)
• Medtronic plc (Ireland)
• Boston Scientific Corporation (U.S.)
• Canon Medical Systems Corporation (Japan)
• FUJIFILM Holdings Corporation (Japan)
• Shimadzu Corporation (Japan)
• Cardinal Health, Inc. (U.S.)
• Becton, Dickinson and Company (U.S.)
• Stryker Corporation (U.S.)
• Edwards Lifesciences Corporation (U.S.)
• Terumo Corporation (Japan)
• W. L. Gore & Associates, Inc. (U.S.)
• Cook Medical LLC (U.S.)
• LeMaitre Vascular, Inc. (U.S.)
• LivaNova PLC (U.K.)

Latest Developments in Global Myxoma Market

• In December 2021, researchers introduced an advanced positron emission tomography (PET) imaging approach using positronium imaging technology to improve early detection of cardiac tumors, including myxomas. The study demonstrated that tumor tissue characteristics could be differentiated at a molecular level, improving early diagnostic accuracy for rare cardiac masses and enhancing the potential for non-invasive tumor characterization. This marked a significant step toward next-generation molecular imaging in cardiac oncology diagnostics
• In August 2023, clinical research highlighted the growing adoption of multimodal imaging techniques such as echocardiography, cardiac MRI, and CT scanning for precise preoperative evaluation of cardiac myxomas. These imaging advancements improved tumor localization, surgical planning, and risk assessment for embolic complications, significantly enhancing patient outcomes in complex cardiac tumor cases. The study emphasized imaging integration as a key development in modern cardiac tumor management
• In April 2024, a comprehensive clinical review reported the increasing use of minimally invasive and robotic-assisted surgical techniques for cardiac myxoma resection. These advancements reduced postoperative complications, shortened hospital stays, and improved recovery outcomes compared to traditional sternotomy procedures. The study also highlighted the growing focus on reducing surgical trauma while maintaining complete tumor excision efficiency
• In March 2024, another clinical advancement review emphasized emerging molecular research approaches for recurrent cardiac myxomas, including genetic screening, epigenetic therapies, and immunotherapy-based experimental strategies. These developments are particularly relevant for patients with Carney complex and recurrent tumors, where conventional surgical approaches alone are insufficient. The research marked a shift toward precision medicine in cardiac tumor management
• In January 2025, updated clinical literature reinforced surgery as the gold-standard treatment for cardiac myxoma while reporting refinements in minimally invasive cardiac surgery techniques. The study highlighted improved surgical outcomes due to better imaging guidance, enhanced intraoperative visualization, and reduced recurrence rates through more precise excision margins. This reflects continuous refinement in surgical oncology practices for benign cardiac tumors

SKU-67570